8-K: Breeze Holdings Warrants and Rights Downgraded to OTCQB Following OTCQX Delisting

Breeze Holdings Acquisition Corp.'s publicly traded warrants and rights will transition from the OTCQX to the OTCQB market after failing to meet continued listing requirements, though its common stock remains on OTCQX and its business combination plans proceed.

Summary

• Breeze Holdings Acquisition Corp. (BRZH) was notified on March 17, 2025, by OTC Markets Group Inc. that its publicly traded warrants (BRZHW) and rights (BRZHR) no longer satisfy OTCQX Market continued qualification requirements.
• The company failed to meet Section 2 of the Requirements for Continued Qualification of the OTCQX Rules for U.S. Companies, specifically Section 1.1(A) of the OTCQX Eligibility Criteria.
• These criteria include requirements for net tangible assets ($2,000,000 for 3+ years operation, or $5,000,000 for less than 3 years), average revenue ($6,000,000 for the last three years), or a bid price of $5 per share for 30 consecutive days, along with specific fiscal year-end financial metrics (net income of $500,000, net tangible assets of $1,000,000, revenues of $2,000,000, or total assets of $5,000,000).
• A 90-day cure period, previously disclosed on March 19, 2025, and amended on March 21, 2025, lapsed without resolution.
• As a result, the company elected to transition the trading of its warrants and rights to the OTCQB market.
• Trading on OTCQB is expected to begin on June 16, 2025, and continue without interruption.
• The company's common stock (BRZH) will continue to trade on the OTCQX.
• Breeze Holdings is continuing to pursue its proposed business combination with YD Biopharma Limited.
• The company expects the transition of warrants and rights to OTCQB will not affect the timing or execution of the business combination plans.

Sentiment

Score: 4

Explanation: The delisting of warrants and rights from OTCQX to OTCQB is a negative event, indicating a failure to meet listing standards. However, the common stock remains on OTCQX, and the company explicitly states its business combination plans are unaffected, which mitigates some of the negative impact.

Positives

• The company's common stock (BRZH) will continue to trade on the OTCQX market.
• The company is continuing to pursue its proposed business combination with YD Biopharma Limited.
• The company expects the transition of warrants and rights to OTCQB will not affect the timing or execution of the business combination plans.

Negatives

• Publicly traded warrants (BRZHW) and rights (BRZHR) no longer satisfy the continued qualification requirements for the OTCQX Market.
• The company failed to meet specific financial and bid price criteria for OTCQX listing.
• A 90-day cure period lapsed without resolution, leading to the delisting.
• Warrants and rights will be transitioned to the OTCQB, a lower tier market.

Risks

• Failure to meet continued listing requirements for OTCQX for warrants and rights, indicating potential underlying financial or operational issues.
• Risk of reduced liquidity or investor interest for warrants and rights trading on the OTCQB market.
• Potential negative perception or impact on investor confidence due to the downgrade of listing tier for certain securities.
• The company's ability to meet future listing requirements for its common stock on OTCQX could be at risk if underlying issues persist.

Future Outlook

Breeze Holdings Acquisition Corp. is continuing to pursue the completion of its proposed business combination with YD Biopharma Limited and expects that the transition of its warrants and rights to OTCQB will not affect the timing or execution of such plans.

Management Comments

• The Company is continuing to pursue the completion of its proposed business combination with YD Biopharma Limited and expects that the transition of its warrants and rights to OTCQB will not affect the timing or execution of such plans.

Industry Context

The transition of a SPAC's warrants and rights from OTCQX to OTCQB typically signals a failure to meet more stringent listing requirements, which can impact investor perception and liquidity for those specific securities. While the common stock remains on OTCQX, the downgrade for other securities might raise questions about the company's financial health or operational stability, especially as it pursues a business combination. For SPACs, maintaining a premium listing is often crucial for attracting target companies and institutional investors.

Stakeholder Impact

• Shareholders (Common Stock): Minimal direct impact as common stock remains on OTCQX, but potential indirect impact from negative perception.
• Warrant and Rights Holders: Direct negative impact due to reduced liquidity and potentially lower investor confidence/interest as these securities move to a lower-tier market (OTCQB).
• Potential Acquisition Target (YD Biopharma Limited): May raise questions about the SPAC's stability or ability to complete the transaction, though the company states it will not affect timing.
• Investors/Market: May view the company as less stable or financially sound due to the inability to meet higher-tier listing requirements for some securities.

Next Steps

• Warrants and rights to begin trading on the OTCQB market on June 16, 2025.
• Continue to pursue the completion of the proposed business combination with YD Biopharma Limited.

Key Dates

Recommendation

Keywords

Breeze Holdings Acquisition Corp., BRZH, SEC filing, 8-K, OTCQX, OTCQB, delisting, warrants, rights, common stock, business combination, YD Biopharma Limited, financial reporting, corporate governance, risk management, SPAC